Anzeige
Mehr »
Donnerstag, 26.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A407ZR | ISIN: NL0015001ZQ0 | Ticker-Symbol: A28A
Frankfurt
24.02.25 | 08:23
0,972 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
AFFIMED NV Chart 1 Jahr
5-Tage-Chart
AFFIMED NV 5-Tage-Chart

Aktuelle News zur AFFIMED Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
28.05.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025509The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN...
► Artikel lesen
21.05.Affimed: Wie das Kurswrack für einen Anlegerkreis zur +500%-Rakete wurde827Wenn Biotech-Aktien scheinbar am Boden liegen, wittern clevere Trader ihre Chance. Ein spektakulärer Trade bei Affimed zeigt, wie aus der Asche eines Insolvenzkandidaten ein echter Rendite-Kracher werden...
► Artikel lesen
AFFIMED Aktie jetzt für 0€ handeln
14.05.Bluebird extends deal deadline; Affimed files for insolvency37
14.05.Cantor Fitzgerald cuts Affimed stock rating on insolvency news18
14.05.Immuno-oncology company Affimed to be delisted from Nasdaq after insolvency filing21
14.05.Affimed shares to be delisted from Nasdaq after insolvency filing15
14.05.Affimed N.V.: Affimed Announces Receipt of Nasdaq Delisting Notice317MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced...
► Artikel lesen
13.05.Affimed N.V. - 6-K, Report of foreign issuer16
13.05.Affimed N.V.: Affimed Announces Filing for the Opening of Insolvency Proceedings388MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...
► Artikel lesen
13.05.Leerink cuts Affimed stock target to $0.39, downgrades rating14
29.04.Affimed N.V.: Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting15
23.04.Affimed N.V.: Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting15
21.04.Affimed N.V. - 6-K, Report of foreign issuer7
21.04.Affimed faces Nasdaq delisting over share price rule21
21.04.Affimed receives Nasdaq non-compliance notice12
21.04.Affimed N.V.: Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement280MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
► Artikel lesen
25.03.Affimed N.V.: Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting376MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
► Artikel lesen
24.02.XFRA DIVERSE INSTRUMENTE: AUSSETZUNG/SUSPENSION1.383DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCASTOR MARITIME...
► Artikel lesen
09.12.24Affimed N.V.: Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)366AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated...
► Artikel lesen
08.12.24Affimed N.V.: Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients288The combination of acimtamig with AlloNK® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R cHL, who have exhausted all standard...
► Artikel lesen
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1